CJC-1295 + Ipamorelin: Scientific Profile
Publicado el · Actualizado el
Research blend of CJC-1295 without DAC (Modified GRF 1-29, GHRH analogue) and Ipamorelin (a GHSR-1a agonist pentapeptide): two GH secretagogues with complementary targets in somatotrophs.
The CJC-1295 (without DAC) + Ipamorelin blend combines two growth hormone (GH) secretagogues used in research on the somatotropic axis. CJC-1295 without DAC, also known as Modified GRF 1-29, is a synthetic analog of the 29 amino acids of GHRH with D-Ala2/Gln8/Ala15/Leu27 substitutions that increase its stability against the DPP-IV enzyme and give it a plasma half-life of ~30 minutes. Ipamorelin is a pentapeptide that is a selective agonist of the ghrelin receptor (GHSR-1a). The mechanism is dual and complementary: CJC-1295 acts on the GHRH receptor (GHRHR) in the pituitary somatotrophs, while Ipamorelin activates GHSR-1a in the same cell through a second pathway, promoting GH release without raising cortisol or prolactin. Neither component has regulatory approval as a medicine. Material intended exclusively for in vitro and preclinical research (RUO).
Mechanism of action
The CJC-1295 + Ipamorelin synergy operates through complementary activation of two distinct receptors on the pituitary somatotroph: (1) CJC-1295 binds to GHRHR (GHRH receptor, coupled to Gs protein), activating the cAMP-PKA cascade that increases transcription of the GH gene, translation, and packaging of secretory granules; the D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷ substitutions confer resistance to degradation by DPP-IV, extending the half-life from minutes (native GHRH) to ~30 minutes; (2) Ipamorelin binds to GHSR-1a (ghrelin receptor, coupled to Gq/11 protein), activating the PLC-IP3-Ca2+ cascade that directly triggers the exocytosis of preformed GH granules. Simultaneous activation of both pathways generates GH pulses 5-10x greater than each agent separately, demonstrated in the classic studies of C.Y. Bowers. Additionally, Ipamorelin partially suppresses the release of somatostatin (SRIF) in the hypothalamus, prolonging the GH pulse. Typical subcutaneous administration generates a GH pulse peaking at 30-60 min and returning to baseline in 2-3 hours, replicating the pulsatile nocturnal physiology. Without elevation of cortisol/prolactin/ACTH due to the selectivity of Ipamorelin.
Mechanism summary
Dual mechanism on pituitary somatotropes: CJC-1295 without DAC (a GHRH analog) acts on the GHRHR receptor, while Ipamorelin (a selective agonist of GHSR-1a) acts through a second pathway, promoting the release of GH without raising cortisol or prolactin.
Estudios Clínicos (10)
- Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog (Jetté, et al. · Endocrinology · 2005) PMID 15817669.
- Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults (Teichman, et al. · Journal of Clinical Endocrinology & Metabolism · 2006) PMID 16352683.
- Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog (Ionescu, et al. · Journal of Clinical Endocrinology & Metabolism · 2006) PMID 17018654.
- Once-Daily Administration of CJC-1295, a Long-Acting Growth Hormone-Releasing Hormone (GHRH) Analog, Normalizes Growth in the GHRH Knockout Mouse (Alba, et al. · American Journal of Physiology - Endocrinology and Metabolism · 2006) PMID 16822960.
- Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone (Bowers, et al. · Journal of Clinical Endocrinology & Metabolism · 1990) PMID 2108187.
- Ipamorelin, the first selective growth hormone secretagogue. (Raun K, et al. · Eur J Endocrinol · 1998) PMID 9849822.
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. (Gobburu JV, et al. · Pharm Res · 1999) PMID 10496658.
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. (Beck DE, et al. · Int J Colorectal Dis · 2014) PMID 25331030.
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. (Mendias CL, et al. · Sports Med · 2026) PMID 41966639.
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. (Dominikowski A, et al. · Front Endocrinol (Lausanne) · 2026) PMID 42395176.
Warnings
CJC-1295 + Ipamorelin is a research-use-only (RUO) compound; the following warnings and handling considerations apply to its laboratory use:
- Experimental combination without regulatory approval
- Theoretical risk of tumor promotion via elevated IGF-1
- Insulin resistance with chronic use
- Carpal tunnel syndrome and arthralgias with prolonged use
- Monitor IGF-1, glucose, HbA1c in chronic protocols
- No long-term combined safety studies in humans
- Active neoplasms
- Decompensated diabetes mellitus
- Proliferative retinopathy
- Hypersensitivity to any component
- Pregnancy and lactation
- Growing children/adolescents
- Severe heart failure
Technical data
- Compound type
- peptide_blend
- Storage
- -20 °C liofilizado; 2-8 °C reconstituido
- Shelf life (lyophilized)
- 24-36 months at 2-8°C
- Shelf life (reconstituted)
- 14-21 days at 2-8°C with bacteriostatic preservative
- Light-sensitive
- Sí
Available for research
CJC-1295 + Ipamorelin está disponible como reactivo for research (RUO):
Frequently asked questions about CJC-1295 + Ipamorelin
What is CJC-1295 + Ipamorelin?
Research blend of CJC-1295 without DAC (Modified GRF 1-29, GHRH analogue) and Ipamorelin (a GHSR-1a agonist pentapeptide): two GH secretagogues with complementary targets in somatotrophs.
What is the mechanism of action of CJC-1295 + Ipamorelin?
Dual mechanism on pituitary somatotropes: CJC-1295 without DAC (a GHRH analog) acts on the GHRHR receptor, while Ipamorelin (a selective agonist of GHSR-1a) acts through a second pathway, promoting the release of GH without raising cortisol or prolactin.
What is CJC-1295 + Ipamorelin researched for?
In preclinical research, CJC-1295 + Ipamorelin is studied mainly in: Research on the somatotropic axis; Models of amplified pulsatile GH release; Studies of sarcopenia and body composition. Material exclusively for scientific research.
How is CJC-1295 + Ipamorelin stored?
Condiciones de conservación: -20 °C liofilizado; 2-8 °C reconstituido; estabilidad liofilizado: 24-36 meses a 2-8°C; una vez reconstituido: 14-21 días a 2-8°C con conservante bacteriostático; protéjase de la luz.
What routes of administration are studied for CJC-1295 + Ipamorelin?
In the research models the following are described: Subcutaneous. Use is exclusively for scientific research.
What precautions should be considered with CJC-1295 + Ipamorelin?
CJC-1295 + Ipamorelin is material for research use only. Experimental combination without regulatory approval. Theoretical risk of tumor promotion via elevated IGF-1.